Business Context and Reporting Period
Company: ORAMED PHARMACEUTICALS INC. (ORMP)
Filing Type: Form 8-K (Current Report)
Date of Report: February 22, 2025
Reporting Period: Event-based report regarding the execution of a material definitive agreement on February 22, 2025.
Key Financial Metrics
This filing is a Current Report (Form 8-K) and does not contain audited financial statements, revenue, profit, cash flow, or balance sheet data. The filing focuses on the terms of a new licensing agreement.
- Revenue Model: The agreement establishes a 50/50 split of Net Revenue generated from the licensed products between the Licensee and Scilex Pharma.
- Commitment: The Licensee is committed to contributing $200,000 annually (or equivalent in kind) toward regulatory efforts until approval is obtained.
Material Changes and Agreements
On February 22, 2025, Scilex Pharmaceuticals, Inc. (a subsidiary of Oramed) entered into a Lido License Agreement with RoyaltyVest Ltd (the "Licensee"), a British Virgin Islands company formed by LidoDev Institutional Investors. Key changes include:
- Superseding Agreement: This agreement supersedes the ZTlido Rest of World Term Sheet announced in October 2024.
- Ownership Structure: Oramed transferred 50% of the Licensee's capital stock to the Company and secured the right to designate half of the Licensee's board of directors.
- Licensed Products: The agreement covers ZTlido (lidocaine topical system) 1.8% and SP-103 (collectively "Lido Products").
- Territory: The Licensee receives an exclusive, worldwide license (excluding the U.S. and certain territories) to develop, manufacture, and commercialize the products.
- Parent Guarantee: Scilex Holding Company provided a Parent Guarantee for Scilex Pharma's obligations, which terminates automatically upon a Change of Control.
Guidance, Outlook, and Obligations
Management commentary is limited to the terms of the agreement. Key operational milestones and obligations include:
- Regulatory Milestone: The Licensee must use commercially reasonable efforts to obtain regulatory approval in at least one "Major Market Country" within 18 months of the effective date.
- Manufacturing: Scilex Pharma must facilitate introductions between the Licensee and current suppliers (Oishi Koseido Co., Ltd. and Itochu Chemical Frontier Corporation) to establish direct engagement for manufacturing.
- Term: The agreement continues until the expiration of the last licensed patent, unless terminated earlier.
Investor Verification Checklist
- Verify the full text of the Lido License Agreement (Exhibit 10.1) for specific definitions of "Net Revenue" and "Major Market Country."
- Confirm the financial status and backing of RoyaltyVest Ltd to ensure it can meet the $200,000 annual commitment and development costs.
- Monitor the timeline for the 18-month regulatory approval milestone in a Major Market Country.
- Review the status of the Parent Guarantee (Exhibit 10.2) and any potential triggers for termination related to a Change of Control.
- Check for subsequent filings regarding the execution of the direct manufacturing agreements with Oishi and Itochu.